The Quantellect read.As of Nov 19, 2026, 12 active firms cover BioNTech SE: 9 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $94.00 to $142.00, a moderate spread. The average target of $123.42 sits 48% above the current $83.24. The rating mix has stayed broadly stable, with Buy-side ratings easing from 10 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.89 next quarter toward $-4.73 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Buy
Strong Buy00%
Buy975%
Neutral325%
Sell00%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$123.42
+48.3% upside
Average target across 12 active firms as of Nov 19, 2026 vs $83.24 current
Highest Target$142.00
Average Target$123.42
Lowest Target$94.00
Detailed analyst forecasts for BNTX
Showing 1–13 of 13 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 9 of 12 active firms rate BNTX a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BNTX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.89
Range $-1.89 – $-1.89 · 1 analysts · -3% YoY
Next period, 1 analysts expect BioNTech SE to earn $-1.89 a share (range $-1.89 – $-1.89), versus $-1.95 a year earlier. Full-year consensus is $-5.09, growing to $-4.73 the year after.
REVENUE · NEXT QUARTER
$153.6M
Range $153.6M – $153.6M · 1 analysts · +30% YoY
Revenue is expected to reach $153.6M (range $153.6M – $153.6M), +30.1% year-over-year. Full-year consensus is $1.9B, rising to $1.9B next year.
Top analysts covering BioNTech SE
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BNTX.
#1
Jessica Fye
JP Morgan · Rank #100
Neutral
No targeton BNTX
Overall win rate
54%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$130.00+56.2% to target
Overall win rate
42%
+ Follow
#3
Terence Flynn
Morgan Stanley · Rank #222
Buy
$114.00+37.0% to target
Overall win rate
36%
+ Follow
#4
Daina Graybosch
Leerink Partners · Rank #396
Neutral
$113.00+35.8% to target
Overall win rate
41%
+ Follow
#5
TA
Tazeen Ahmad
B of A Securities · Rank #411
Buy
$108.00+29.7% to target
Overall win rate
46%
+ Follow
BNTX stock forecast FAQ
What is BNTX's average 12-month price target?+
The 12 active firms with a live target average $123.42 for BioNTech SE over the next 12 months, ranging from a $142.00 high to a $94.00 low, as of Nov 19, 2026.
Is BNTX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 12 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BNTX?+
The Street-high target is $142.00 (Goldman Sachs), and the Street-low is $94.00 (TD Cowen). The average of all 12 active-firm targets is $123.42.
How many active Wall Street firms cover BNTX?+
12 active firms have a recognized rating on BioNTech SE as of Nov 19, 2026, and 12 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BNTX?+
Among analysts who currently cover BNTX, Jessica Fye of JP Morgan has the strongest overall Quantellect track record (Rank #100). Their current call is Neutral.
What is BioNTech SE's projected EPS for next quarter?+
The consensus estimate is $-1.89 per share (range $-1.89 – $-1.89) across 1 analysts. Full-year EPS is projected at $-5.09, rising to $-4.73 the following year.
How much revenue is BioNTech SE expected to report next quarter?+
Consensus revenue is $153.6M (range $153.6M – $153.6M). Full-year revenue is projected at $1.9B, growing to $1.9B next year.
Have analysts been upgrading or downgrading BNTX lately?+
As of Nov 19, 2026, 9 of 12 active firms rate BNTX a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BNTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.